Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PCSK9-IN-11 (compound 5r) is a potent PCSK9 inhibitor with oral activity. PCSK9-IN-11 shows inhibitory activity of PCSK9 transcription in HepG2 cells (IC50= 5.7 μM). PCSK9-IN-11 can increase LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 11,000 | |||
10 mg | 在庫あり | ¥ 18,500 | |||
25 mg | 在庫あり | ¥ 37,500 | |||
50 mg | 在庫あり | ¥ 60,500 | |||
100 mg | 在庫あり | ¥ 94,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 16,500 |
説明 | PCSK9-IN-11 (compound 5r) is a potent PCSK9 inhibitor with oral activity. PCSK9-IN-11 shows inhibitory activity of PCSK9 transcription in HepG2 cells (IC50= 5.7 μM). PCSK9-IN-11 can increase LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research. |
In vitro | PCSK9-IN-11 (compound 5r) (0-25 μM, 24 h) significantly reduces PCSK9 protein levels and increases LDLR expression in a dose dependent manner[1]. |
In vivo | PCSK9-IN-11 (compound 5r) (0-1000 mg/kg, gavage, once) exhibits better safety characteristics in vivo, with a half lethal dose (LD50) value exceeding 1000 mg/kg. PCSK9-IN-11 (30 mg/kg, gavage, once a day, lasting for 8 weeks) significantly inhibits liver PCSK9 expression and slightly decreases serum PCSK9 levels [1]. |
分子量 | 381.79 |
分子式 | C16H17ClFN5O3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.82 mg/mL (10 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PCSK9-IN-11 Others PCSK9IN11 Inhibitor inhibitor inhibit